Fairfield, Bush & Co’s Idexx Laboratories IDXX Stock Holding History

Fairfield, Bush & Co’s Portfolio IDXX Stock Details IDXX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-3	Closed	-$1.67K	–	264
2023 Q4	$1.67K	Buy	+3	New	+$1.41K	﹤0.01%	402

Other funds holding IDXX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Fundsmith LLP London, United Kingdom $13.6B AUM 7.6% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BAMCO Inc New York $66.6B AUM 7.35% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Fairfield, Bush & Co's IDXX Position: Q1 2024 in Review

Fairfield, Bush & Co sold out of Idexx Laboratories (IDXX) in Q1 2024, closing a stake of 3 shares — an estimated $1.67K sold.

Fairfield, Bush & Co first reported a position in IDXX in Q4 2023 and held it in 1 quarter. The position peaked at $1.67K in Q4 2023. 1,149 funds tracked by Wall St. Rank hold IDXX as of Q1 2024.

Fairfield, Bush & Co reported no remaining Idexx Laboratories position as of Q1 2024 after selling out during the quarter.
Fairfield, Bush & Co sold 3 Idexx Laboratories shares in Q1 2024, an estimated $1.67K.
Fairfield, Bush & Co first reported a position in Idexx Laboratories in Q4 2023 and held it in 1 quarter.
Fairfield, Bush & Co's Idexx Laboratories position peaked at $1.67K in Q4 2023.
1,149 funds tracked by Wall St. Rank held Idexx Laboratories as of Q1 2024.

Based on Fairfield, Bush & Co's 13F filing for Q1 2024, filed 15 May 2024.